Electronic Acknowledgement Receipt

EFS ID:	1252248
Application Number:	10682178
Confirmation Number:	7316
Title of Invention:	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
First Named Inventor:	Charles J. Link
Customer Number:	22885
Filer:	Heidi S. Nebel/Patricia Wilson
Filer Authorized By:	Heidi S. Nebel
Attorney Docket Number:	P05859US01
Receipt Date:	13-OCT-2006
Filing Date:	09-OCT-2003
Time Stamp:	15:15:20
Application Type:	Utility
International Application Number:	

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1		LINK_P05859US01_RESP_10-13-06_HSN.pdf	386183	yes	13

	Multipart Description		
	Doc Desc	**Start**	**End**
	Amendment - After Non-Final Rejection	1	1
	Claims	2	12
	Applicant Arguments/Remarks Made in an Amendment	13	13

Warnings:	
Information:	
Total Files Size (in bytes):	386183

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.